NDAORALTABLET
Approved
Oct 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IOSAT is an oral potassium iodide tablet approved in 1982 for radiation emergency preparedness and thyroid protection. It is a simple inorganic salt that blocks thyroid uptake of radioactive iodine during nuclear incidents or radiological events. The drug represents a critical public health countermeasure rather than a commercial therapeutic.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal commercial investment, this brand operates as a specialized niche asset with small, functionally-focused teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Careers on IOSAT are heavily weighted toward operations, manufacturing, and technical maintenance rather than commercial or medical roles. This product offers stability through government contracting and public health partnerships, but limited growth in traditional pharma career tracks.
ELECTRICIANMECHANICAL MAINTENANCE TECHNICIAN I
Worked on IOSAT at Mission Pharmacal? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.